Calidi Biotherapeutics, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 7.23 million compared to USD 6.46 million a year ago. Basic loss per share from continuing operations was USD 0.2 compared to USD 0.75 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.151 USD | -6.85% |
|
-23.42% | -89.74% |
Jul. 05 | Calidi Biotherapeutics to Implement 1-For-10 Reverse Stock Split | MT |
Jul. 02 | Calidi Biotherapeutics, Inc. announced that it has received $0.6 million in funding | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-89.74% | 10.41M | |
+18.39% | 124B | |
+18.44% | 114B | |
+20.79% | 25.83B | |
-23.87% | 19.42B | |
-18.19% | 16.2B | |
-20.22% | 15.31B | |
+56.97% | 14.32B | |
+6.01% | 14.31B | |
-49.33% | 14.19B |
- Stock Market
- Equities
- CLDI Stock
- News Calidi Biotherapeutics, Inc.
- Calidi Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024